DE60018119T2 - Verfahren zur herstellung von polymorphen des clarithromycins - Google Patents
Verfahren zur herstellung von polymorphen des clarithromycins Download PDFInfo
- Publication number
- DE60018119T2 DE60018119T2 DE60018119T DE60018119T DE60018119T2 DE 60018119 T2 DE60018119 T2 DE 60018119T2 DE 60018119 T DE60018119 T DE 60018119T DE 60018119 T DE60018119 T DE 60018119T DE 60018119 T2 DE60018119 T2 DE 60018119T2
- Authority
- DE
- Germany
- Prior art keywords
- clarithromycin
- water
- slurrying
- erythromycin
- takes place
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 title claims abstract description 114
- 229960002626 clarithromycin Drugs 0.000 title claims abstract description 84
- 238000004519 manufacturing process Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960003276 erythromycin Drugs 0.000 claims abstract description 14
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 13
- 229930006677 Erythromycin A Natural products 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000002002 slurry Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000012453 solvate Substances 0.000 description 7
- 238000000634 powder X-ray diffraction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000003386 deoximation reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- -1 2-methoxyprop-2-yl Chemical group 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940087430 biaxin Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- FGRVOLIFQGXPCT-UHFFFAOYSA-L dipotassium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [K+].[K+].[O-]S([O-])(=O)=S FGRVOLIFQGXPCT-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- DDNRNCSGIYDEMC-UHFFFAOYSA-N ethanol;formic acid Chemical compound CCO.OC=O DDNRNCSGIYDEMC-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 229940075931 sodium dithionate Drugs 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- JXAZAUKOWVKTLO-UHFFFAOYSA-L sodium pyrosulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OS([O-])(=O)=O JXAZAUKOWVKTLO-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17547700P | 2000-01-11 | 2000-01-11 | |
| US175477P | 2000-01-11 | ||
| PCT/US2000/033844 WO2001051059A1 (en) | 2000-01-11 | 2000-12-15 | Processes for preparing clarithromycin polymorphs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60018119D1 DE60018119D1 (de) | 2005-03-17 |
| DE60018119T2 true DE60018119T2 (de) | 2006-05-04 |
Family
ID=22640371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60018119T Expired - Fee Related DE60018119T2 (de) | 2000-01-11 | 2000-12-15 | Verfahren zur herstellung von polymorphen des clarithromycins |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6624292B2 (OSRAM) |
| EP (1) | EP1280535B1 (OSRAM) |
| JP (1) | JP2003519661A (OSRAM) |
| KR (1) | KR20020071012A (OSRAM) |
| CN (1) | CN1450903A (OSRAM) |
| AT (1) | ATE288758T1 (OSRAM) |
| AU (2) | AU2001222619C1 (OSRAM) |
| BR (1) | BR0016992A (OSRAM) |
| CA (1) | CA2397092A1 (OSRAM) |
| DE (1) | DE60018119T2 (OSRAM) |
| DK (1) | DK1280535T3 (OSRAM) |
| ES (1) | ES2236023T3 (OSRAM) |
| HR (1) | HRP20020572A2 (OSRAM) |
| HU (1) | HUP0204252A3 (OSRAM) |
| IL (1) | IL150698A0 (OSRAM) |
| IS (1) | IS6463A (OSRAM) |
| PL (1) | PL356645A1 (OSRAM) |
| PT (1) | PT1280535E (OSRAM) |
| RU (1) | RU2002118308A (OSRAM) |
| SI (1) | SI1280535T1 (OSRAM) |
| WO (1) | WO2001051059A1 (OSRAM) |
| ZA (1) | ZA200205229B (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2002116232A (ru) * | 1999-12-16 | 2004-01-10 | Тева Фамэситикл Индастрис Лтд. (Il) | Способ получения полиморфных модификаций кларитромицина и новой полиморфной модификации IV |
| CA2397092A1 (en) * | 2000-01-11 | 2001-07-19 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin polymorphs |
| US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| KR20030047873A (ko) * | 2000-02-29 | 2003-06-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물 |
| US20030099715A1 (en) * | 2000-03-28 | 2003-05-29 | Schwarz Franz Xaver | Granulated particles with masked taste |
| US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| PT1285659E (pt) * | 2001-08-13 | 2007-10-09 | Fond Salvatore Maugeri Clinica | Uso de composições claritromicinas no fabrico de um medicamento para o tratamento de artrite deformante |
| US20060083759A1 (en) * | 2002-07-17 | 2006-04-20 | Aleksander Resman | Stabilization of the profile of release of active substances from a formulation |
| WO2005009365A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| AU2004258953B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| AU2004258944B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| EP1653925A1 (en) | 2003-08-11 | 2006-05-10 | Advancis Pharmaceutical Corporation | Robust pellet |
| CA2535398C (en) | 2003-08-12 | 2013-11-12 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| JP5686494B2 (ja) * | 2003-08-29 | 2015-03-18 | シオノギ インコーポレイテッド | 抗生物質製剤、その使用法及び作成方法 |
| EP1663169A4 (en) | 2003-09-15 | 2010-11-24 | Middlebrook Pharmaceuticals In | ANTIBIOTICS, ITS USE AND FORMULATION |
| WO2005061524A2 (en) * | 2003-12-22 | 2005-07-07 | Ranbaxy Laboratories Limited | Process for the preparation of form ii clarithromycin |
| US20050142187A1 (en) * | 2003-12-24 | 2005-06-30 | Treacy Donald J.Jr. | Enhanced absorption of modified release dosage forms |
| CN1960825A (zh) * | 2004-01-28 | 2007-05-09 | 细胞免疫科学公司 | 官能化胶态金属组合物和方法 |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| JP2008505124A (ja) | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | パルス送達用錠剤 |
| WO2007008537A2 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International, Limited | Nanoparticulate clarithromycin formulations |
| WO2007064595A2 (en) * | 2005-11-29 | 2007-06-07 | Bausch & Lomb Incorporated | Fluocinolone acetonide drug substance polymorphic interconversion |
| US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| WO2011026234A1 (en) * | 2009-09-02 | 2011-03-10 | Bernard Charles Sherman | Clarithromycin extended-release tablet |
| MX2021001169A (es) | 2013-11-15 | 2023-02-10 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2473525A1 (fr) | 1980-01-11 | 1981-07-17 | Roussel Uclaf | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| US4331803A (en) | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
| JPS60214796A (ja) | 1984-04-06 | 1985-10-28 | Taisho Pharmaceut Co Ltd | ６−０−メチルエリスロマイシン類の製法 |
| JPS61103890A (ja) | 1984-10-26 | 1986-05-22 | Taisho Pharmaceut Co Ltd | ６−０−メチルエリスロマイシンａ誘導体 |
| US4670549A (en) | 1985-03-18 | 1987-06-02 | Taisho Pharmaceutical Co., Ltd. | Method for selective methylation of erythromycin a derivatives |
| US4672056A (en) | 1985-11-12 | 1987-06-09 | Abbott Laboratories | Erythromycin A derivatives and method of use |
| US4640910A (en) | 1985-11-12 | 1987-02-03 | Abbott Laboratories | Erythromycin A silylated compounds and method of use |
| KR960000434B1 (ko) | 1986-12-17 | 1996-01-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 에리스로마이신 a유도체 및 그의 제조 방법 |
| GB8721165D0 (en) | 1987-09-09 | 1987-10-14 | Beecham Group Plc | Chemical compounds |
| JP2751385B2 (ja) | 1988-05-19 | 1998-05-18 | 大正製薬株式会社 | エリスロマイシンａオキシム及びその塩の製造方法 |
| US5440505A (en) * | 1994-01-21 | 1995-08-08 | Intel Corporation | Method and circuitry for storing discrete amounts of charge in a single memory element |
| US5756473A (en) | 1995-11-21 | 1998-05-26 | Abbott Laboratories | 6-O-methyl erythromycin D and process for making |
| US5872229A (en) | 1995-11-21 | 1999-02-16 | Abbott Laboratories | Process for 6-O-alkylation of erythromycin derivatives |
| US5719272A (en) | 1996-04-02 | 1998-02-17 | Abbott Laboratories | 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives |
| US5837829A (en) | 1996-04-02 | 1998-11-17 | Abbott Laboratories | 9-oximesilyl erythromycin a derivatives |
| US5808017A (en) | 1996-04-10 | 1998-09-15 | Abbott Laboratories | Process for preparing erythromycin A oxime |
| AU733646B2 (en) * | 1996-07-29 | 2001-05-17 | Bgp Products Operations Gmbh | Preparation of crystal form II of clarithromycin |
| US5844105A (en) * | 1996-07-29 | 1998-12-01 | Abbott Laboratories | Preparation of crystal form II of clarithromycin |
| US5858986A (en) | 1996-07-29 | 1999-01-12 | Abbott Laboratories | Crystal form I of clarithromycin |
| US5945405A (en) | 1997-01-17 | 1999-08-31 | Abbott Laboratories | Crystal form O of clarithromycin |
| US5864023A (en) | 1997-02-13 | 1999-01-26 | Abbott Laboratories | 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives |
| US5852180A (en) | 1997-11-17 | 1998-12-22 | Abbott Laboratories | Chemical synthesis of 6-O-alkyl erythromycin A |
| US5932710A (en) | 1997-12-01 | 1999-08-03 | Abbott Laboratories | Process for preparing 6-O-alkyl-9-oxime erythromycin B |
| US5892008A (en) | 1997-12-16 | 1999-04-06 | Abbott Laboratories | Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives |
| KR100377159B1 (ko) * | 1998-09-09 | 2003-08-19 | 한미약품공업 주식회사 | 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법 |
| RU2002116232A (ru) * | 1999-12-16 | 2004-01-10 | Тева Фамэситикл Индастрис Лтд. (Il) | Способ получения полиморфных модификаций кларитромицина и новой полиморфной модификации IV |
| CA2397092A1 (en) * | 2000-01-11 | 2001-07-19 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin polymorphs |
| KR20030047873A (ko) * | 2000-02-29 | 2003-06-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물 |
-
2000
- 2000-12-15 CA CA002397092A patent/CA2397092A1/en not_active Abandoned
- 2000-12-15 CN CN00819302A patent/CN1450903A/zh active Pending
- 2000-12-15 US US09/736,446 patent/US6624292B2/en not_active Expired - Fee Related
- 2000-12-15 IL IL15069800A patent/IL150698A0/xx unknown
- 2000-12-15 DK DK00986367T patent/DK1280535T3/da active
- 2000-12-15 HU HU0204252A patent/HUP0204252A3/hu unknown
- 2000-12-15 AU AU2001222619A patent/AU2001222619C1/en not_active Ceased
- 2000-12-15 KR KR1020027008908A patent/KR20020071012A/ko not_active Ceased
- 2000-12-15 EP EP00986367A patent/EP1280535B1/en not_active Revoked
- 2000-12-15 DE DE60018119T patent/DE60018119T2/de not_active Expired - Fee Related
- 2000-12-15 SI SI200030650T patent/SI1280535T1/xx unknown
- 2000-12-15 WO PCT/US2000/033844 patent/WO2001051059A1/en not_active Ceased
- 2000-12-15 PL PL00356645A patent/PL356645A1/xx not_active Application Discontinuation
- 2000-12-15 PT PT00986367T patent/PT1280535E/pt unknown
- 2000-12-15 JP JP2001551483A patent/JP2003519661A/ja not_active Withdrawn
- 2000-12-15 RU RU2002118308/15A patent/RU2002118308A/ru unknown
- 2000-12-15 HR HR20020572A patent/HRP20020572A2/hr not_active Application Discontinuation
- 2000-12-15 AU AU2261901A patent/AU2261901A/xx active Pending
- 2000-12-15 ES ES00986367T patent/ES2236023T3/es not_active Expired - Lifetime
- 2000-12-15 BR BR0016992-7A patent/BR0016992A/pt not_active Application Discontinuation
- 2000-12-15 AT AT00986367T patent/ATE288758T1/de not_active IP Right Cessation
-
2002
- 2002-06-28 ZA ZA200205229A patent/ZA200205229B/en unknown
- 2002-07-09 IS IS6463A patent/IS6463A/is unknown
-
2003
- 2003-06-10 US US10/459,178 patent/US6987175B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1280535A4 (en) | 2003-02-05 |
| DE60018119D1 (de) | 2005-03-17 |
| EP1280535A1 (en) | 2003-02-05 |
| PL356645A1 (en) | 2004-06-28 |
| CA2397092A1 (en) | 2001-07-19 |
| HUP0204252A3 (en) | 2003-04-28 |
| HRP20020572A2 (en) | 2005-04-30 |
| ZA200205229B (en) | 2003-06-30 |
| IS6463A (is) | 2002-07-09 |
| KR20020071012A (ko) | 2002-09-11 |
| DK1280535T3 (da) | 2005-04-04 |
| US20030216555A1 (en) | 2003-11-20 |
| BR0016992A (pt) | 2002-12-31 |
| CN1450903A (zh) | 2003-10-22 |
| SI1280535T1 (OSRAM) | 2005-08-31 |
| PT1280535E (pt) | 2005-04-29 |
| AU2001222619B8 (en) | 2005-07-14 |
| ATE288758T1 (de) | 2005-02-15 |
| RU2002118308A (ru) | 2004-02-20 |
| US6987175B2 (en) | 2006-01-17 |
| HUP0204252A2 (hu) | 2003-03-28 |
| IL150698A0 (en) | 2003-02-12 |
| AU2001222619C1 (en) | 2006-01-12 |
| EP1280535B1 (en) | 2005-02-09 |
| JP2003519661A (ja) | 2003-06-24 |
| ES2236023T3 (es) | 2005-07-16 |
| AU2001222619B2 (en) | 2005-04-28 |
| WO2001051059A1 (en) | 2001-07-19 |
| AU2261901A (en) | 2001-07-24 |
| US6624292B2 (en) | 2003-09-23 |
| US20020028920A1 (en) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60018119T2 (de) | Verfahren zur herstellung von polymorphen des clarithromycins | |
| DE60022230T2 (de) | Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv | |
| DE69726577T2 (de) | Kristallin form i von clarithromycin | |
| DE69730138T2 (de) | Herstellung von kristallinen form ii von clarithromycin | |
| DE60111438T2 (de) | Verfahren zur Herstellung von einer kristallinen Form II von Clarythromycin | |
| DE60209704T2 (de) | Neue kristallforme von azithromycin | |
| DE60220180T2 (de) | 14 bis 15 gliedrige makrolide mit antibakterieller aktivität | |
| DE69712610T2 (de) | Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel | |
| DE69921192T2 (de) | Ethanolate des azithromycin, herstllungsverfahren und deren pharmazeutische zusammenstellungen | |
| DE69908338T2 (de) | 15-gliedrige ketolid-lactame mit antibakterieller wirkung | |
| DE60102171T2 (de) | Ketolidantibiotika | |
| EP2024383A2 (de) | Kristalline formen von 11beta-(4-acetylphenyl)-20,20,21,21,21-pentafluor-17alpha- hydroxy-19-nor-17 -pregna-4,9-dien-3-on | |
| DD211565A5 (de) | Verfahren zur herstellung von 4"-epi-erythromycin a und derivaten hiervon als brauchbare antibakterielle mittel | |
| DE60200298T2 (de) | Verbessertes Verfahren zur Herstellung von non-hygroscopischem Azithromycin Dihydrat | |
| DE2614669C2 (de) | Gamma-kristalline wasserfreie Form von 7-(D-alpha-Formyloxy-alpha-phenylacetamido)-3-(1-methyl-1H-tetrazol-5- ylthiomethyl)-3-cephem-4-natriumcarboxylat und Verfahren zu ihrer Herstellung | |
| DE2740950C2 (OSRAM) | ||
| DE2953969C2 (OSRAM) | ||
| DE2722032A1 (de) | 9-(3,5-di-o-acyl-beta-d-arabinofuranosyl)-adenin-verbindungen | |
| DE60204024T2 (de) | 9a-n-[n'-(phenylsulfonyl)carbamoyl] derivate von 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a und von 5-o-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolid a | |
| DE69614936T2 (de) | d4T polymorphe Form I Verfahren | |
| DE2537375A1 (de) | 9,3'',4''-triacylester des antibiotikums sf-837 m tief 1 sowie verfahren zur herstellung derselben | |
| DE2310329A1 (de) | Arabinofuranosylcytosine und verfahren zu ihrer herstellung | |
| DE602004003054T2 (de) | Neue 3-decladinosyl-9a-n-carbamoyl- und 9a-n-thiocarbamoylderivate von 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a | |
| DE60102232T2 (de) | Kosteneffektive methode zur selektiven methylierung von erythromycin a-derivaten | |
| DE60017399T2 (de) | Diphosphat-salz von einem 4"-substitutierte-9-deoxo-9a-aza-9a-homoerythromyin-derivat und seine pharmazeutische zubereitung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8339 | Ceased/non-payment of the annual fee |